Tel Aviv Medical Center
Combination induces durable responses in advanced multiple myeloma
The combination of talquetamab and teclistamab induced durable responses among patients with relapsed or refractory multiple myeloma, according to phase 1B/phase 2 study results.
COVID-19 prevention must extend beyond vaccines for patients receiving cell therapies
Infection mitigation with vaccines is essential for patients with hematologic malignancies because they are at increased risk for severe infection, hospitalization and mortality if they contract COVID-19.
SITC presents annual awards highlighting achievements in cancer immunotherapy
The Society for Immunotherapy of Cancer will honor several recipients with its annual awards, presented this week during its 36th Annual Meeting & Pre-Conference Programs.
Exposure to common nonantimicrobial drugs may lead to drug-resistant infections
Exposure to commonly prescribed nonantimicrobial drugs was associated with an increased risk for drug-resistant infections in a study of more than 1,800 patients at an Israeli hospital, researchers reported at the ECCMID virtual meeting.